Last update July 31, 2018

Spirapril Hydrochloride

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Spirapril and its active metabolite spiraprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension.
Oral administration once day.

Since the last update we have not found published data on its excretion in breastmilk.

Other compounds from the same group (ACEI) are not excreted in breastmilk in significant amounts, but until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable (Anderson 2018).

Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).

The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).

Alternatives

  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Enalapril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Spirapril Hydrochloride in other languages or writings:

Group

Spirapril Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Spirapril Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 45 - 50 %
Molecular weight 503 daltons
Protein Binding 89 %
VD 0.4 - 0.6 l/Kg
pKa 3.62 -
Tmax 2 - 3 hours
T½ 30 - 35 hours

References

  1. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  2. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  4. Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Press Suppl. 1994 Abstract

Total visits

2,610

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM